Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.

This grant in Europe complements the ones already obtained in November 2020 in the United States and in November 2021 in Singapore, protecting glenzocimab until 2036 as well. The patent is also
under examination in other countries such as Japan.

To date, three patent families, including 4 granted patents and 33 pending patent applications, protect glenzocimab and its therapeutic use.

Sophie Binay, Chief Operating Officer and Chief Scientific Officer, comments “The grant of this patent in Europe, protecting the use of glenzocimab in thrombotic diseases, represents an important step for the development of our drug candidate and its future commercialization and strengthens Acticor’s patent portfolio. It has been extended to other major territories with the grant of a patent in the United States and an intention of grant in Japan, providing protection until 2036. In addition, thanks to its historical commitments with INSERM, Acticor Biotech has exclusive rights to the commercial exploitation of this patent.

Related posts

acticor
admin

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Read More »
DigitalHealth
admin

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.

Read More »